Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Ovarian low malignant potential tumor
Results 1-13 of 13 for your search:
Start Over
Vaccine Therapy in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC29810, NCI-2011-00285, NCT01312389
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Erismodegib and Paclitaxel in Treating Patients with Recurrent Ovarian Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: UAB 1357, NCI-2015-01335, F140214007, NCT02195973
Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Sym013-01, NCI-2016-01802, NCT02906670
Nintedanib in Treating Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Previously Treated with Bevacizumab
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00033060, NCI-2013-00455, NCT01669798
Surgery with or without Carboplatin in Treating Patients with Recurrent Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 21
Trial IDs: 12-275, NCI-2013-00405, NCT01767675
LY2606368 in Treating Patients with BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple-Negative Breast Cancer, High Grade Ovarian Cancer, or Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0156, NCI-2014-02304, 140156, 342996, P131428, NCT02203513
Carboplatin and Gemcitabine Hydrochloride with or without ATR Kinase Inhibitor VX-970 in Treating Patients with Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1563, NCI-2015-02064, 9948, NCT02627443
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: I 270715, NCI-2016-00534, NCT02853318
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8808, NCI-2011-02500, CDR0000700997, UPCI 10-115, NCT01366144
Online Coping Skills Curriculum in Improving Quality of Life in Cancer Patients and Survivors with Chronic Pain
Status: Active
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: Pro00061381, NCI-2015-00756, NCT02465892
Folate Receptor in Diagnosing Ovarian Cancer using Serum Samples from Patients with Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 18 and over
Trial IDs: 2015-024, NCI-2015-01039, 1504013983, NCT02520115
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
Start Over